The Roles of SHCBP1 in Cancer Hallmarks: Molecular Mechanisms and Therapeutic Implications
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26188778 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Hye-Youn Kim und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Lee Gil Ya Cancer and Diabetes Institute, Gachon University College of Medicine, Incheon 21999, Republic of Korea. Hauptthemen laut MEDLINE: Neoplasms, Src Homology 2 Domain-Containing, Transforming Protein 1. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 112 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT), Basic Science Research Capacity Enhancement Project through Korea Basic Science Institute, Gachon University research fund of 2023.
Abstract (Originalsprache)
The SHCBP1 (SHC SH2-domain-binding protein 1) is identified as an important regulator of cancer biology, participating in the modulation of multiple cancer hallmarks. Initially discovered as a component of the mitotic midbody essential for cytokinesis, SHCBP1 is now recognized for orchestrating a broad spectrum of oncogenic processes such as persistent proliferation, apoptosis resistance, epithelial–mesenchymal transition, and immune system evasion. This review comprehensively explores the molecular features of SHCBP1, its regulatory networks, and its multifaceted roles in cancer progression. SHCBP1 is commonly overexpressed in diverse cancers, with elevated expression levels strongly associated with more aggressive tumors and unfavorable patient prognosis. Mechanistically, SHCBP1 serves as a potential mediator of oncogenic signaling pathways, thereby regulating mitotic processes, transcriptional alterations, and cytoskeletal reorganization. In addition to its biological functions, SHCBP1 offers translational promise as a prognostic marker and a prospective therapeutic target. Preclinical models indicate that genetic depletion or pharmacologic disruption of SHCBP1 limits tumor growth, increases sensitivity to chemotherapy, and reduces metastatic capacity. Despite significant progress, the development of selective SHCBP1 inhibitors remain challenging areas. This review summarizes SHCBP1’s diverse roles in tumor pathogenesis and outlines future research directions to develop SHCBP1-targeted strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry, Lee Gil Ya Cancer and Diabetes Institute, Gachon University College of Medicine, Incheon 21999, Republic of Korea.
- Department of Health Sciences and Technology, Gachon Advanced Institute for Health Sciences and Technology, Gachon University, Incheon 21999, Republic of Korea.
ORCID-Profile: Hye-Youn Kim, Suntaek Hong
Förderung
- National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT)
- Basic Science Research Capacity Enhancement Project through Korea Basic Science Institute
- Gachon University research fund of 2023
- National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT)
Zitieren
APA
Kim, H. Y., Park, Y. J., Ryu, S., & Hong, S. (2025). The Roles of SHCBP1 in Cancer Hallmarks: Molecular Mechanisms and Therapeutic Implications. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26188778
Vancouver
Kim HY, Park YJ, Ryu S, Hong S. The Roles of SHCBP1 in Cancer Hallmarks: Molecular Mechanisms and Therapeutic Implications. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26188778
BibTeX
@article{Kim2025,
author = {Kim, Hye-Youn and Park, Ye-Jin and Ryu, Soyeon and Hong, Suntaek},
title = {The Roles of SHCBP1 in Cancer Hallmarks: Molecular Mechanisms and Therapeutic Implications},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26188778}
}
EUVIMED